8-K
filed January 30, 2024, 6:59 PM ET
CIK 0001907685
other material
confidence high
sentiment negative
materiality 1.00
Comera Life Sciences Holdings, Inc.: restructuring charge — Comera terminates all employees after Regeneron deal failure triggers default on $1.5M notes
Comera Life Sciences Holdings, Inc.
- Regeneron notified Jan 26 it won't negotiate license under research collaboration; triggers Event of Default on $1.5M 12% Senior Secured Convertible Notes.
- Board approved termination of all employees, including CEO Jeff Hackman, CFO Michael Campbell, CSO Robert Mahoney, effective Jan 31, 2024.
- CFO Campbell terminated then rehired as consultant CEO/CFO at $2,400/day; Hackman and Wexler resigned from board.
- Purchasers of December 2023 notes withdrew prior exercise of Share Purchase Option to acquire remaining common stock.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Comera Life Sciences Holdings, Inc. reported a default on senior notes of $1.5 million in aggregate original principal amount with holders of 12.0% Senior Secured Convertible Notes due December 29, 2024 at 12.0% maturing December 29, 2024.
- Instrument
- senior notes
- Principal
- $1.5 million in aggregate original principal amount
- Counterparty
- holders of 12.0% Senior Secured Convertible Notes due December 29, 2024
- Rate
- 12.0%
- Maturity
- December 29, 2024
- Event
- default
Exact text from the filing
On January 29, 2024, Comera Life Sciences Holdings, Inc. (the “Company”) delivered a notice (the “Event of Default Notice”) to the holders (the “Holders”) of its outstanding 12.0% Senior Secured Convertible Notes due December 29, 2024 (collectively, the “Notes”), of which $1.5 million in aggregate original principal amount is outstanding. The Event of Default Notice notified the Holders that the Regeneron Event (as defined in Item 8.01 below) occurred on January 26, 2024 and constituted a Material Adverse Effect (as defined in the Notes) and an Event of Default (as defined in the Notes).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeff Hackman was terminated as President, Chief Executive Officer and Director at Comera Life Sciences Holdings, Inc..
- Action
- terminated
- Role
- President, Chief Executive Officer and Director
Exact text from the filing
the Company terminated the employment of Jeff Hackman, President, Chief Executive Officer and Director, Michael Campbell, Executive Vice President and Chief Financial Officer, and Robert Mahoney, Chief Scientific Officer effective January 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William Wexler resigned as Director at Comera Life Sciences Holdings, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
William Wexler resigned from the Company’s board of directors effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Campbell was terminated as Executive Vice President and Chief Financial Officer at Comera Life Sciences Holdings, Inc..
- Action
- terminated
- Role
- Executive Vice President and Chief Financial Officer
Exact text from the filing
the Company terminated the employment of Jeff Hackman, President, Chief Executive Officer and Director, Michael Campbell, Executive Vice President and Chief Financial Officer, and Robert Mahoney, Chief Scientific Officer effective January 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Mahoney was terminated as Chief Scientific Officer at Comera Life Sciences Holdings, Inc..
- Action
- terminated
- Role
- Chief Scientific Officer
Exact text from the filing
the Company terminated the employment of Jeff Hackman, President, Chief Executive Officer and Director, Michael Campbell, Executive Vice President and Chief Financial Officer, and Robert Mahoney, Chief Scientific Officer effective January 31, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Campbell was appointed as Chief Executive Officer and Chief Financial Officer at Comera Life Sciences Holdings, Inc..
- Action
- appointed
- Role
- Chief Executive Officer and Chief Financial Officer
Exact text from the filing
the Company engaged Mr. Campbell as a consultant and appointed him to serve as the Company’s Chief Executive Officer and Chief Financial Officer effective immediately following the termination of his employment on January 31, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Comera Life Sciences Holdings, Inc. announced a restructuring (all of the Company’s employees, including all of its executive officers).
- Type
- restructuring
- Headcount
- all of the Company’s employees, including all of its executive officers
Exact text from the filing
On January 29, 2024, the Company’s board of directors approved the termination of all of the Company’s employees, including all of its executive officers, effective as of January 31, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.